NCT04838808View on ClinicalTrials.gov

Rivaroxaban in Type 2 Myocardial Infarctions

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

May 12, 2022

Study Completion Date

January 3, 2023

Conditions
Type II Myocardial Infarction
Interventions
DRUG

Rivaroxaban 2.5 MG [Xarelto]

Rivaroxaban 2.5mg twice daily for 90-days

DRUG

Placebo

Placebo tablet twice daily for 90-days

Trial Locations (1)

T6W 1T7

University of Alberta, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT04838808 - Rivaroxaban in Type 2 Myocardial Infarctions | Biotech Hunter | Biotech Hunter